A Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Children

An Open-label, Intravenous to Oral Switch, Multiple Dose Multi-Centre Study to Investigate the Pharmacokinetics, Safety and Tolerability of Voriconazole in Hospitalized Children Aged 2 to 12 Years Who Require Treatment for the Prevention of Systemic Fungal Infections.

This is a study to investigate the pharmacokinetics, safety and tolerability of several doses of voriconazole, intravenous and oral suspension formulations, in children

Inclusion Criteria:

• Children who require a systemic antifungal agent for the prevention of systemic fungal infection

Exclusion Criteria:

• Children who are receiving medications which cannot be taken concomitantly with voriconazole.